Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

Support Care Cancer. 2022 Feb;30(2):1015-1018. doi: 10.1007/s00520-021-06606-x.

Authors

Ronald Chow¹, Rudolph M Navari², Bryan Terry³, Carlo DeAngelis⁴, Elizabeth Horn Prsic³

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ronald.chow@mail.utoronto.ca.
² World Health Organization, Geneva, Switzerland.
³ Yale New Haven Hospital, Yale School of Medicine, Yale University, New Haven, CT, USA.
⁴ Sunnybrook Health Sciences Centre, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.

PMID: 34613472
DOI: 10.1007/s00520-021-06606-x

No abstract available

Publication types

Editorial
Meta-Analysis

MeSH terms

Antiemetics* / therapeutic use
Antineoplastic Agents* / adverse effects
Benzodiazepines
Humans
Nausea / chemically induced
Nausea / drug therapy
Nausea / prevention & control
Network Meta-Analysis
Olanzapine / therapeutic use
Vomiting / chemically induced
Vomiting / drug therapy
Vomiting / prevention & control

Substances

Antiemetics
Antineoplastic Agents
Benzodiazepines
Olanzapine

Grants and funding

001/WHO_/World Health Organization/International